XML 44 R30.htm IDEA: XBRL DOCUMENT v3.25.3

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Provisions for Sales and Allowances

A rollforward of the Company’s provisions for sales discounts and allowances is as follows:

		Nine Months Ended September 30, 2025
(In thousands)		Contractual Adjustments(1)				Discounts(2)				Product Returns				Other				Total
Beginning balance — December 31, 2024		$	228,978			$	43,645			$	50,507			$	13,297			$	336,427
Current provisions relating to sales in current year			404,353				312,419				19,841				67,803				804,416
Adjustments relating to prior years			(34,939	)			156				(7,302	)			(373	)			(42,458	)
Payments relating to sales in current year			(260,213	)			(293,195	)			—				(55,560	)			(608,968	)
Payments relating to sales in prior years			(127,928	)			(23,940	)			(9,569	)			(12,512	)			(173,949	)
Ending balance — September 30, 2025		$	210,251			$	39,085			$	53,477			$	12,655			$	315,468

1.“Contractual Adjustments” include “Medicaid Rebates” and “Medicare Part D” accruals.

2.“Discounts” include “Chargebacks” and “Product Discounts.”

Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets

Total revenue-related reserves as of September 30, 2025 and December 31, 2024 included in the accompanying consolidated balance sheets are summarized as follows:

		September 30,				December 31,
(In thousands)		2025				2024
Reduction of accounts receivable		$	19,249			$	22,031
Components of accrued sales discounts, allowances and reserves			252,743				272,452
Components of other long-term liabilities			43,476				41,944
Total revenue-related reserves		$	315,468			$	336,427

Schedule of Contract Assets and Contract Liabilities

Total contract assets at September 30, 2025 were as follows:

(In thousands)		Contract Assets
Contract assets at December 31, 2024		$	4,990
Additions			4,483
Transferred to receivables, net			(8,756	)
Contract assets at September 30, 2025		$	717

Total contract liabilities at September 30, 2025 were as follows:

(In thousands)		Contract Liabilities
Contract liabilities at December 31, 2024		$	1,249
Additions			1,313
Amounts recognized into revenue			(2,562	)
Contract liabilities at September 30, 2025		$	—

Product sales, net

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2025 and 2024, the Company recorded product sales, net, as follows:

		Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands)		2025				2024				2025				2024
VIVITROL		$	121,125			$	113,650			$	343,781			$	323,182
ARISTADA and ARISTADA INITIO			98,050				84,652				272,820				249,571
LYBALVI			98,248				74,697				252,550				203,055
Total product sales, net		$	317,423			$	272,999			$	869,151			$	775,808

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2025 and 2024, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

		Three Months Ended September 30, 2025												Nine Months Ended September 30, 2025
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total				Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	30,180			$	30,180			$	—			$	78,240			$	78,240
VUMERITY			3,494				32,122				35,616				16,852				85,996				102,848
RISPERDAL CONSTA			3,732				19				3,751				16,659				41				16,700
Other			1,562				5,653				7,215				9,171				15,242				24,413
		$	8,788			$	67,974			$	76,762			$	42,682			$	179,519			$	222,201

		Three Months Ended September 30, 2024												Nine Months Ended September 30, 2024
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total				Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	58,448			$	58,448			$	—			$	199,860			$	199,860
VUMERITY			8,753				23,821				32,574				30,740				68,322				99,062
RISPERDAL CONSTA			2,417				11				2,428				8,440				264				8,704
Other			4,777				6,917				11,694				27,077				17,132				44,209
		$	15,947			$	89,197			$	105,144			$	66,257			$	285,578			$	351,835

(1)“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X

- Definition

Revenue related reserves included in consolidated balance sheets.

+ References

No definition available.

+ Details

Name:	alks_RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix:	alks_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13

+ Details

Name:	us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: